Australia's most trusted
source of pharma news
Sunday, 16 March 2025
Posted 19 August 2024 AM
Big pharmas have a chance to launch a serious contender in the obesity market to challenge Novo Nordisk and Eli Lilly's GLP-1s, if they're prepared to make a deal.
Zealand Pharma has announced it's looking for a partner to develop and commercialise its weight-loss drug petrelintide, one that shares its vision of framing the obesity landscape.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.